We are very happy to announce that the Velux Stiftung has decided to support our research on healthy aging. As stated on their website: "The foundation aims to have an impact on and contribute to sustainable improvement and the benefit of society. This is achieved by supporting the creation of new knowledge through cutting-edge research and the fostering of its application and dissemination. The foundation attains leverage by focusing on projects with a high potential to initiate change and impact." Our lab is dedicated to contribute to the achievment of these aims and highly appreciates the support of the foundation! 

SRF Einstein has broadcasted an episode about Alzheimer's on Swiss national television. Our collaborator Prof. Tony Wyss-Coray from Stanford University and his work are in the focus of this episode. Take a look!

We welcome our new lab members Robin van Brummelen and Pascal Guntern! Great to have you guys on board! 

On December 15, 2017 we are organizing the 2nd Type-2 Immunity Meeting Bern. Registration is mandatory and abstract submission is open now. Check out the preliminary program and have a look at the plenary speakers on the T2IMB website. We hope to see you there! 

We are happy and very grateful that the Swiss and Bernese "Lungenliga" have decided to support our project on new approaches to treat allergic asthma. These studies will be carried out together with the research group of Prof. Christophe von Garnier. We are looking forward to the collaboration.  

Our former PhD student Dr. Fabian Zellweger has recently published an original article on the regulation of allergic reactions via CD32b as well as a review article on the latest reports on IgE-related allergic disorders developent. We congratulate him for this great achievement!

Our PhD student Fabian Zellweger has been awarded an Abstract Prize for his work on the regulation of allergic reactions via CD32b at the 2016 European Academy of Allergy and Clinical Immunology Conference in Vienna. Congratulations! 

Together with our collaborators Prof. Theodore Jardetzky and Prof. Kari Nadeau from Stanford University we have published an interesting study on the "Structural basis of Omalizumab therapy and Omalizumab-mediated IgE exchange" in Nature Communicaitons. 

Under the guidance of Prof. Peter M. Villiger our colleagues from the Department of Rheumatology, Immunology and Allergology have published an interesting, phase 2, randomised, double-blind, placebo-controlled study about the use of Tocilizumab for the treatment of giant cell arteritis in The Lancet. We congratulate the authors to this remarkable achievment!!!

In a collaboration with the Group of Prof. Trajkovski from the University of Geneva Prof. Sigfried Hapfelmeier from the Institute for Infectious Disease at the University of Bern has lately published two outstanding papers in Nature Medicine and Cell. We congratulate the authors to this remarkable achievment.